UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Risk of self-harm and the use of leukotriene receptor antagonists and inhaled corticosteroids: a population-based study

Chen, Boqing; Yuen, Andrew SC; Man, Kenneth KC; Hayes, Joseph F; Osborn, David PJ; Wong, Ian CK; Chan, Adrienne YL; ... Lau, Wallis CY; + view all (2025) Risk of self-harm and the use of leukotriene receptor antagonists and inhaled corticosteroids: a population-based study. Journal of Allergy and Clinical Immunology: In Practice (In press).

[thumbnail of Manuscript_LTRAs and self-harm.pdf] Text
Manuscript_LTRAs and self-harm.pdf - Accepted Version
Access restricted to UCL open access staff until 19 February 2026.

Download (490kB)

Abstract

Background: Whether leukotriene receptor antagonists (LTRAs) or inhaled corticosteroids (ICS) use can increase the risk of self-harm remains unclear. / / Objective: To evaluate the association between self-harm and use of LTRA and ICS among patients with asthma. / / Methods: This self-controlled case series (SCCS) study used data from the UK Clinical Practice Research Datalink linked to hospital and mortality records. We included patients with asthma aged ≥10 years who had at least one prescription of LTRA, one prescription of ICS, and an incident self-harm during 2005-2020. Incidence rate ratios (IRRs) of self-harm during (presented in order of precedence if they overlapped): pre-LTRA, pre-ICS, LTRA-alone, ICS-alone, and combination use of LTRA and ICS, versus non-use, were calculated using conditional Poisson regression model. Additional analyses using SCCS extension, case-case-time-control, and cohort study designs were used to examine robustness of results. / / Results: Among 313,943 individuals prescribed LTRA and ICS, 2,900 had incident self-harm. IRRs were 0.77 (95%CI=0.58-1.01) during pre-LTRA, 0.68 (95%CI=0.57-0.82) during LTRA-alone, and 0.70 (95%CI=0.56-0.86) during combination use. Further analysis suggested the self-harm incidence was lower during the first 90 days of LTRA use (IRR=0.74; 95%CI=0.58-0.95), before returning to non-use level (IRR=0.93; 95%CI=0.74-1.17). Comparable incidence to non-use was observed during pre-ICS (IRR=0.99; 95%CI=0.71-1.39) and ICS-alone (IRR=0.88; 95%CI=0.75-1.04). The results were robust across sensitivity analyses and study designs, which did not suggest increased risk of self-harm with LTRA/ICS use. / / Conclusion: Using the SCCS design, which was based on comparisons within a population with both the outcome and exposure of interest, our study does not support an association between self-harm and LTRA or ICS in patients with asthma.

Type: Article
Title: Risk of self-harm and the use of leukotriene receptor antagonists and inhaled corticosteroids: a population-based study
Publisher version: https://www.journals.elsevier.com/the-journal-of-a...
Language: English
Additional information: This version is the author-accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Asthma, Self-harm, Leukotriene receptor antagonists (LTRAs), Inhaled corticosteroids (ICS), Self-controlled case series (SCCS), Incidence rate ratios (IRRs), UK Clinical Practice Research Datalink, Pharmacoepidemiology, Drug safety
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy
URI: https://discovery.ucl.ac.uk/id/eprint/10214082
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item